Synthon (the “Company”), a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced that the Private Equity business at Goldman Sachs Alternatives will acquire a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company. Synthon is a vertically integrated global leader in the development, manufacture, and out-licensing of complex generics and hybrid medicines for patients around the world. Headquartered in the Netherlands, Synthon has approximately 1,600 employees and operates four research laboratories and four manufacturing sites located in the Czech Republic, Spain, Chile, and Argentina.
Read the full article: Synthon, a Global Leader in Complex Generic Drug Development and Manufacturing, Announces Investment from Goldman Sachs Alternatives //
Source: https://www.synthon.com/en/contact/press-and-media/synthon-a-global-leader-in-complex-generic-drug-development-and-manufacturing-announces-investment-from-goldman-sachs-alternatives